Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04578041
Other study ID # 20-01101
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date January 1, 2023
Est. completion date March 5, 2023

Study information

Verified date December 2023
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is aimed to test the efficacy of 10 sessions of Transcranial Rotating Permanent Magnetic Stimulation (TRPMS) paired with aerobic exercise or computerized cognitive training (CT) on mobility and depression symptoms in 40 individuals affected by multiple sclerosis (MS). Participants in Arm 1 will complete 10x40 minutes daily sessions of TRPMS+aerobic exercise. Participants in Arm 2 will complete TRPMS+computerized CT. Primary outcomes for both arms will be assessed at baseline, at treatment end and after 4-week from the treatment end (follow-up).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 5, 2023
Est. primary completion date March 5, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: In order to be eligible to participate in Arm 1 of this study, an individual must meet all of the following criteria: 1. Between ages 18 - 70 2. SDMT z-score = -3.0 3. Wide Range Achievement Test-4th Edition (WRAT-4) Reading Recognition scaled score = 85 4. Definite MS diagnosis as assessed by a licensed physician (all subtypes - RRMS, PPMS, SPMS) 5. Expanded Disability Status Scale (EDSS) = 6.5 6. Clinically stable disease course with absence of relapse within the past 30 days 7. Able to understand the informed consent process and provide consent to participate in the study 8. Complete the TMS screening questionnaire 9. Able to commit to study timeframe 10. Clinically significant gate deviations (T25-FW > 5.0 seconds) 11. Able to walk independently with or without assistive device (i.e. cane, crutches, or walking frames) for medium distance 12. Able to exercise with seated elliptical machine In order to be eligible to participate in Arm 2 of this study, an individual must meet all of the following criteria: 1. Between ages 18 - 70 2. SDMT z-score = -3.0 3. Wide Range Achievement Test-4th Edition (WRAT-4) Reading Recognition scaled score = 85 4. Definite MS diagnosis as assessed by a licensed physician (all subtypes - RRMS, PPMS, SPMS) 5. Expanded Disability Status Scale (EDSS) = 6.5 6. Clinically stable disease course with absence of relapse within the past 30 days 7. Able to understand the informed consent process and provide consent to participate in the study 8. Complete the TMS screening questionnaire 9. Able to commit to study timeframe 10. Elevated symptoms of depression as determined by BDI of = 4 Exclusion Criteria: 1. Visual, auditory or motor deficits that would influence participant safety as assessed by a licensed physician 2. History of seizure or epileptic history as assessed by licensed physician 3. Medication which significantly lower the seizure threshold as assessed by licensed physician 4. Primary psychiatric disorder that would influence ability to participate 5. Uncontrolled headaches and migraine or recent changes in the rate or severity of head pressure, headache, or migraine in the past two weeks 6. History of stroke or head trauma (e.g., head injury, brain surgery) or medical device implanted in the head (e.g. Deep Brain Stimulator) or in the neck (e.g. Vagus Nerve Stimulator) 7. History of uncontrolled or labile hypertension 8. Other serious uncontrolled medical condition or recent medical traumas 9. Presence of metal or electronic implants in the body contraindicated for TMS 10. Alcohol or other substance use disorder 11. Pregnant or breastfeeding 12. History of clinically significant abnormalities on electrocardiogram (EKG) (Arm 1 only) 13. Presence of chronic medical illness and/or severe ataxia (Arm 1 only) 14. Functional surgery for lower limb in the past 6 months (e.g. hip or knee replacement) (Arm 1 only) 15. Lower limb Botulinum toxin injection within the past 2 months (Arm 1 only)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
TRPMS (Transcranial Rotating Permanent Magnet Stimulation)
TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet. Modality: Excitatory stimulation Frequency: 5 Hz Interval between stimulus: 100 ms Duration of each stimulus: 25 ms Duration of stimulation: 40 minutes Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2
Other:
Aerobic Exercise Program
Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
Computerized CT (Cognitive Training)
Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training. The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of Sessions Completed Feasibility of at-home usage of TRPMS device measured by percent of sessions completed (80%) Day 10
Primary Change in Gait Velocity To determine the primary efficacy of the TRPMS intervention paired with aerobic exercise, gait velocity will be assessed during the instrumented 10-meter walking test. Gait velocity will be measured using a wearable inertial sensor (G-Sensor). Baseline (Day 0), Day 10
Primary Change in PROMIS Depression Score Arm 2: To determine the primary efficacy of the TRPMS intervention paired with computerized CT, changes in PROMIS Depression from baseline to treatment-end will be measured. The PROMIS Depression questionnaire consists of 8 items. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression. Baseline (Day 0), Day 10
Secondary Change in Gait Velocity Arm 1: To assess sustained improvements, gait velocity will be assessed during the instrumented 10-meter walking test. Gait velocity will be measured using a wearable inertial sensor (G-Sensor). Baseline (Day 0), Week 4
Secondary Change in Distance Traveled During 2-Minute Walking Test Arm 1 Baseline (Day 0), Day 10
Secondary Change in the Total Time for Completing the Timed Up and Go (TUG) test Arm 1: The test requires the subject to rise from a chair, walk 3.0 m at a comfortable pace to a mark placed on the floor, turn around at the 3.0 m mark, walk back to the starting point, and return to sitting in the chair. Baseline (Day 0), Day 10
Secondary Change in Modified Fatigue Impact Scale (MFIS) Score MFIS consists of 21 statements that describe the effects of fatigue. Each statement is scored on a scale of 0-4 (0 = never, 1 = rarely, 2 = sometimes, 3 = often, 4 = almost always). The total MFIS score can range from 0-84; the higher the score, the stronger the feelings of fatigue. Baseline (Day 0), Day 10
Secondary Change in Short Form (SF)-36 Score The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. Baseline (Day 0), Day 10
Secondary Change in PROMIS Depression Score Arm 2: To determine the primary efficacy of the TRPMS intervention paired with computerized CT, changes in PROMIS Depression from baseline to treatment-end will be measured. The PROMIS Depression questionnaire consists of 8 items. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression. Baseline (Day 0), Week 4
Secondary Change in Center for Epidemiological Studies-Depression short form (CESD-10) Score Arm 2: CESD-10 10-item Likert scale questionnaire assessing depressive symptoms in the past week. It includes three items on depressed affect, five items on somatic symptoms, and two on positive affect. Options for each item range from "rarely or none of the time" (score of 0) to "all of the time" (score of 3). The total range of score is 0-30; higher scores indicate the presence of significant depressive symptoms. Baseline (Day 0), Day 10
Secondary Change in Patient Health Questionnaire 9 (PHQ-9) Score Arm 2: The PHQ-9 is the depression module, which scores each of the nine DSM-IV criteria as "0" (not at all) to "3" (nearly every day). A PHQ-9 score =10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. Baseline (Day 0), Day 10
Secondary Change in Inventory of Depressive Symptomatology Self-Report (IDS-SR) Score Arm 2: Each of the 28 items is scored on a 1 to 3 scale (0-the absence of pathology; 3-severe pathology). The total scores range from 0 to 84. The higher the score, the more severe the pathology. Baseline (Day 0), Day 10
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4